Rhythm Pharmaceuticals
RYTM
126 hedge funds and large institutions have $1.08B invested in Rhythm Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 46 increasing their positions, 23 reducing their positions, and 18 closing their positions.
298% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $3.25M
100% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 23
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
11% more funds holding
Funds holding: 114 → 126 (+12)
4.02% less ownership
Funds ownership: 110.34% → 106.32% (-4%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
41% less capital invested
Capital invested by funds: $1.81B → $1.08B (-$734M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$17.5M |
| 2 |
Millennium Management
New York
|
+$12.7M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$12.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.39M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$6.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$60.6M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$50.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$14.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$9.73M |
| 5 |
Alkeon Capital Management
New York
|
-$5.58M |
RYTM Hedge Fund Activity: Q1 2023 in Review
126 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2023, worth a combined $1.08B — down 41% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RYTM positions and 18 closed out — a net gain of 12 holders — while 46 added to existing stakes and 23 trimmed.
The largest buyer was Primecap Management, adding an estimated $17.5M. The largest seller was Federated Hermes, cutting an estimated $60.6M.
- 126 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2023, up from 114 in Q4 2022.
- Funds reported $1.08B of Rhythm Pharmaceuticals stock for Q1 2023, down 41% quarter-over-quarter.
- 30 funds opened new Rhythm Pharmaceuticals positions in Q1 2023 and 18 closed out, a net change of +12 holders.
- The largest Rhythm Pharmaceuticals buyer in Q1 2023 was Primecap Management, an estimated $17.5M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2023 was Federated Hermes, an estimated $60.6M sold.
Based on aggregated 13F filings for Q1 2023.